Premium
Cross‐protective efficacy from a immunogen firstly identified in L eishmania infantum against tegumentary leishmaniasis
Author(s) -
Martins V. T.,
Lage D. P.,
Duarte M. C.,
Costa L. E.,
ChávezFumagalli M. A.,
Roatt B. M.,
MenezesSouza D.,
Tavares C. A. P.,
Coelho E. A. F.
Publication year - 2016
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12304
Subject(s) - immunogen , leishmania infantum , biology , leishmaniasis , immunology , leishmania , cross reactions , microbiology and biotechnology , virology , visceral leishmaniasis , antigen , parasite hosting , antibody , computer science , monoclonal antibody , world wide web
Summary Experimental vaccine candidates have been evaluated to prevent leishmaniasis, but no commercial vaccine has been proved to be effective against more than one parasite species. LiHyT is a Leishmania ‐specific protein that was firstly identified as protective against Leishmania infantum . In this study, LiHyT was evaluated as a vaccine to against two Leishmania species causing tegumentary leishmaniasis ( TL ): Leishmania major and Leishmania braziliensis . BALB /c mice were immunized with rLiHyT plus saponin and lately challenged with promastigotes of the two parasite species. The immune response generated was evaluated before and 10 weeks after infection, as well as the parasite burden at this time after infection. The vaccination induced a Th1 response, which was characterized by the production of IFN ‐γ, IL ‐12 and GM ‐ CSF , as well as by high levels of IgG2a antibodies, after in vitro stimulation using both the protein and parasite extracts. After challenge, vaccinated mice showed significant reductions in their infected footpads, as well as in the parasite burden in the tissue and organs evaluated, when compared to the control groups. The anti‐ Leishmania Th1 response was maintained after infection, being the IFN ‐γ production based mainly on CD 4 + T cells. We described one conserved Leishmania ‐specific protein that could compose a pan‐ Leishmania vaccine.